HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells by Masanobu Tsubaki, Taira Matsuo, Rie Komori, Noriaki Nagai, Tetsushi Yamamoto, Shozo Nishida

“…Abstract Background Chronic myeloid leukemia is associated with a more favorable prognosis following treatment with BCR::ABL1 tyrosine kinase inhibitors (TKIs). Nonetheless, about 40% of affected individuals with CML display resistance or intolerance towards BCR::ABL1 TKIs. …”
Get full text

Promising horizons in achondroplasia along with the development of new drugs by Keiichi Ozono, Takuo Kubota, Toshimi Michigami

“…Additionally in development are a tyrosine kinase inhibitor, a soluble FGFR3, an antibody against FGFR3, meclizine, and the FGF2-aptamer. …”
Get full text

Maternal prediabetes as a risk factor of preeclampsia and placental dysfunction in pregnant female Sprague-Dawley rats by Aneliswe Siboto, Asiphaphola Ludidi, Ntethelelo Sibiya, Andile Khathi, Phikelelani Ngubane

“…Placental vascular endothelial growth factor (VEGF), placenta growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1) mRNA expression were measured terminally. …”
Get full text

An In silico Approach towards Finding the Cancer-Causing Mutations in Human MET Gene by Fayeza Sadia Laskar, Md. Nazmul Islam Bappy, Md. Sowrov Hossain, Zenifer Alam, Dilruba Afrin, Sudeb Saha, Kazi Md. Ali Zinnah

“…Mesenchymal–epithelial transition (MET) factor is a proto-oncogene encoding tyrosine kinase receptor with hepatocyte growth factor (HGF) or scatter factor (SF). …”
Get full text

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy by Ninna Aggerholm-Pedersen, Christina Demuth, Akmal Safwat, Peter Meldgaard, Moustapha Kassem, Boe Sandahl Sorensen

“…An immortalised nontransformed human stromal (mesenchymal) stem cell line hMSC-TERT4 and a transformed cell line hMSC-TERT20-CE8, known to form sarcoma-like tumours when implanted in immune-deficient mice, were used as models. Receptor tyrosine kinase (RTK) activation was analysed by RTK arrays and cellular viability after tyrosine kinases inhibitor (TKI) treatment with or without doxorubicin was assessed by MTS assay. …”
Get full text

Real-world assessment to estimate multiple attributes related to treatment cost driver for mantle cell lymphoma in Japan by econometric modeling by Saaya Tsutsué, Shinichi Makita, Hiroya Asou, Anila Mathew, Yuki Kado, Koki Idehara, Seok-Won Kim, Dilinuer Ainiwaer

“…SEM analysis revealed Bruton tyrosine kinase inhibitor-based treatment as a cost driver (β: 0.398 [0.340; 0.457], p < 0.001). …”
Get full text

Structural basis for the interaction between the Drosophila RTK Sevenless (dROS1) and the GPCR BOSS by Jianan Zhang, Yuko Tsutsui, Hengyi Li, Tongqing Li, Yueyue Wang, Salma Laraki, Sofia Alarcon-Frias, Steven E. Stayrook, Daryl E. Klein

“…Abstract Sevenless, the Drosophila homologue of ROS1 (University of Rochester Sarcoma) (herein, dROS1) is a receptor tyrosine kinase (RTK) essential for the differentiation of Drosophila R7 photoreceptor cells. …”
Get full text

Antifibrotic Effect of Combination of Nilotinib and Stem Cell-Conditioned Media on CCl4-Induced Liver Fibrosis by Gamal Shiha, Ahmed Nabil, Ahmed Lotfy, Reham Soliman, Ayman A. Hassan, Islam S. Ali, Doaa F. Gad, Faten Zahran

“…Nilotinib is a second-generation tyrosine kinase inhibitor, which showed antifibrotic efficacy. …”
Get full text

An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma by Prajwal Boddu, C. Cameron Yin, Rashmi Kanagal-Shamanna, Guillin Tang, Beenu Thakral, Tapan Kadia, Marina Konopleva, Elias Jabbour, Nitin Jain

“…Had it not been for this fortuitous discovery, the patient would not have been treated with tyrosine kinase inhibitors. We emphasize that FISH and PCR testing for BCR-ABL1 rearrangement are integral to arriving at an accurate diagnosis and should be routinely tested on B-LBL biopsy specimens.…”
Get full text

Molecular cloning of EZH2 oncogene in chronic myeloid leukemia and therapeutic prospects by Juliana Costa Gaspar, Lucas Santos de Santana, Camila Menezes Freire de Souza, Marcos Montani Caseiro, Rosane Rezende de Souza Giuliani, Cleide Barbieri de Souza

“…Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia, caused in 95 % of the cases by a cytogenetic abnormality characterized by the reciprocal translocation between chromosomes 9 and 22 t(9; 22) (q34; q11), resulting in Philadelphia chromosome (Ph).Considering that CML cure is only possible with a successful bone marrow transplantation and that there are resistance cases to the tyrosine kinase inhibitor Imatinib Mesylate, prescribed in first line drug treatment; it is important to know in detail the genes and proteins that are possibly altered in CML, favoring effective therapeutic strategies, optimized diagnosis and minimal residual disease detection. …”
Get full text

Safety of brigatinib following alectinib-induced-pneumonitis: Case report by Blerina Resuli, Heidi Galarza, Laura Elsner, Diego Kauffmann-Guerrero, Jürgen Behr, Amanda Tufman

“…Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) show robust efficacy and has revolutionized the treatment of NSCLC patients harboring an ALK-rearrangement. …”
Get full text

Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome by Hua Bai, Dongming Zhou, Jinwen Liu, Jie He, Zhou Min, Wenyong Fan, Bing Chen, Yong Xu

“…This case suggests that bortezomib may be considered as a potential treatment option for SchS, in addition to anti-IL-1 therapies and bruton tyrosine kinase (BTK) inhibitors.…”
Get full text

Isolated central nervous system relapse in blast crisis of chronic myeloid leukemia: a case report by Hari Priya Raghvan, Caroline Ho Siew Ling, Wee Shiang Yui, Boo Yang Liang, Ehram Jamian, Indhira Subbiah

“…A 46-year-old female with underlying CML in lymphoid blast crisis, previously treated with chemotherapy and tyrosine kinase inhibitors, presented with visual disturbances. …”
Get full text

Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2pos Breast Cancer by Nirmala Ghimirey, Chase Steele, Brian J. Czerniecki, Gary K. Koski, Loral E. Showalter

“…To explore the possibility of combining targeted drugs with Th1-polarizing vaccines, we undertook a study to examine the impact of combining Th1 cytokines with the relatively broad-spectrum receptor tyrosine kinase antagonist, sunitinib. We found that when a panel of five phenotypically diverse human breast cancer cell lines was subjected to treatment with sunitinib plus recombinant Th1 cytokines IFN-γ and TNF-α, synergistic effects were observed across a number of parameters including different aspects of apoptotic cell death. …”
Get full text

Mucosal Epithelial Jak Kinases in Health and Diseases by Narendra Kumar, Longxiang Kuang, Ryan Villa, Priyam Kumar, Jayshree Mishra

“…Janus kinases (Jaks) are a family of nonreceptor tyrosine kinase that include four different members, viz., Jak1, Jak2, Jak3, and Tyk2. …”
Get full text

Altered Forebrain Functional Connectivity and Neurotransmission in a Kinase-Inactive Mouse Model of Autism by Shiyu Tang PhD, Elizabeth M. Powell PhD, Wenjun Zhu MS, Fu-Sun Lo MD, Reha S. Erzurumlu PhD, Su Xu PhD

“…MET , the gene encoding the tyrosine kinase receptor for hepatocyte growth factor, is a susceptibility gene for autism spectrum disorder (ASD). …”
Get full text

AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer by Pierre-Antoine Bannier, Charlie Saillard, Philipp Mann, Maxime Touzot, Charles Maussion, Christian Matek, Niklas Klümper, Johannes Breyer, Ralph Wirtz, Danijel Sikic, Bernd Schmitz-Dräger, Bernd Wullich, Arndt Hartmann, Sebastian Försch, Markus Eckstein

“…Selective targeting of FGFR3 hotspot mutations with tyrosine kinase inhibitors (e.g., erdafitinib) is approved for mUC and requires FGFR3 mutational testing. …”
Get full text

Determination of Crizotinib in Mouse Tissues by LC-MS/MS and Its Application to a Tissue Distribution Study by Fang Zhao, Yuan Wei, Yiming Yan, Han Liu, Sitong Zhou, Bo Ren, Ruijuan Liu

“…Toxicity induced by crizotinib, a small-molecule tyrosine kinase inhibitor, is a significant clinical issue during treatment. …”
Get full text

Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements by Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah Young Shin, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Jeong Uk Lim, Chang Dong Yeo

“…Background and objectives: This study aimed to compare the efficacy of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and brigatinib in the treatment of advanced non-small-cell lung cancer (NSCLC) with ALK rearrangements based on real-world data. …”
Get full text

Immunotherapy versus targeted therapy in management of recurrent squamous cell carcinoma of oral tongue by Nadimul Hoda, Aastha Moza, K.P. Amith, K.S. Sabitha

“…Agents frequently reported to be associated with oral complications include tyrosine kinase inhibitors (TKIs), inhibitors of the VEGF receptor (VEGFR), anti-epidermal growth factor receptor (anti-EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin inhibitors (mTORis), and, more recently, immune checkpoint inhibitors (ICIs). …”
Get full text